Literature DB >> 9336720

Follicular lymphomas: do histologic subtypes predict outcome?

T P Miller1, M LeBlanc, T M Grogan, R I Fisher.   

Abstract

There has been a long history of debate as to whether histologic subtypes of follicular lymphoma are associated with unique outcomes. The controversy has been fueled by studies of small patient groups having heterogeneous prognostic factors followed for short intervals, and by a new proposal for the classification of lymphomas (REAL). The current report provides insight into the controversy by using a large group of patients of similar stage and treatment followed for up to 25 years.

Entities:  

Mesh:

Year:  1997        PMID: 9336720     DOI: 10.1016/s0889-8588(05)70468-8

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  5 in total

1.  Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.

Authors:  Patrizia Mondello; Normann Steiner; Wolfgang Willenbacher; Claudio Cerchione; Davide Nappi; Endri Mauro; Simone Ferrero; Salvatore Cuzzocrea; Michael Mian
Journal:  Oncologist       Date:  2018-01-09

Review 2.  Clinical and molecular prognostic factors in follicular lymphoma.

Authors:  Andrew J Davies
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

3.  Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

Authors:  Jonathan W Friedberg; Michelle Byrtek; Brian K Link; Christopher Flowers; Michael Taylor; John Hainsworth; James R Cerhan; Andrew D Zelenetz; Jamie Hirata; Thomas P Miller
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

Review 4.  Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How.

Authors:  Francesca Pavanello; Sara Steffanoni; Michele Ghielmini; Emanuele Zucca
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-11-07       Impact factor: 2.576

5.  Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?

Authors:  I Chau; R Jones; D Cunningham; A Wotherspoon; N Maisey; A R Norman; P Jain; L Bishop; A Horwich; D Catovsky
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.